Heatwurx Inc.

PCSA Healthcare Biotechnology

In the quarter to June 2026, EPS grew 81.0% and free cash flow grew 20.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.88 0.02 +1.08%
Market cap
$5.2M
P/E
1.8×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−251.45
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
3.76 2.54 0.98 0.87
Net Debt/EBITDA
1.81 1.50 0.51 0.08
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(1.83) (2.87) (1.56) (0.66)
Book value per Share
3.07 4.26 0.97 (0.12)
Free Cash Flow
(3.48) (3.75) (4.09) (1.81)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates